Clinical trials: Inoperable Disease
Hepatic Malignant Tumors, Pancreatic Cancer
Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy
The objectives of this study are to study the safety and effect of IRE as a treatment for inoperable hepatic and pancreatic malignancy.
- Trial name
- IRE (NCT02822716)
- Testing
- IRE treatment, Ultrasound
- Where
- Hong Kong
- Volunteers
- 11 people
- Sponsor
- Chinese University of Hong Kong
Rectal Cancer, Adenocarcinoma
HDR Endorectal Brachytherapy With 3D-Printed Guidance and Local Shielding for Rectal Cancer Organ Preservation
This prospective, single-center, single-arm phase II study will evaluate the efficacy, safety, and technical feasibility of an organ-preserving radiotherapy strategy for patients with localized rectal adenocarcinoma who are…
- Trial name
- NOM-HDR-W (NCT07786493)
- Testing
- High-Dose-Rate Endorectal Brachytherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer, Metastatic Cancer
Dexamethasone and Supportive Care With or Without Whole-Brain Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer That Has Spread to the Brain and Cannot Be Removed By Surgery
RATIONALE: Steroid therapy, such as dexamethasone, may reduce swelling, pain, and other symptoms of inflammation and may be effective in treating some of the problems caused by cancer and cancer treatment.
- Trial name
- NCT00403065
- Testing
- dexamethasone, quality-of-life assessment, radiation therapy
- Where
- 70 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Medical Research Council
Esophageal Cancer
Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer
This trial is going to evaluate the efficacy and safety of IMRT / nab-TP chemotherapy for unresectable esophageal cancer, and to investigate the optimal concurrent chemotherapy regimen for local advanced and unresectable…
- Trial name
- NCT02762474
- Testing
- nab-paclitaxel group
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
This study will implement a new treatment regimen for patients with advanced and inoperable pancreatic cancer using chemotherapy combinations of Folfirinox or gemcitabine-nab paclitaxel (abraxane) followed by a short course of…
- Conditions
- Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer, Pancreatic Cancer
- Trial name
- NCT03600623
- Testing
- Folfirinox, Gemcitabine nab-Paclitaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Non-small Cell Lung Cancer
Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
Stereotactic body radiation therapy (SBRT) is a special form of treatment which pinpoints high doses of radiation directly to cancer.
- Trial name
- NCT01525446
- Testing
- SBRT with proton beam radiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Renal Cell Carcinoma
Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT
This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).
- Trial name
- AQuOS-II (NCT05023265)
- Testing
- Stereotactic body radiotherapy
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Sunnybrook Health Sciences Centre
Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
This phase II trial studies how well talimogene laherparepvec works in treating patients with breast cancer that has come back and cannot be removed by surgery.
- Conditions
- Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT02658812
- Testing
- Laboratory Biomarker Analysis, Talimogene Laherparepvec
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer
Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin
In this study, the investigators will use P-HDFL, a regimen with high tumor remission rate (~ 60-70%) and with only modest treatment-associated toxicities, as induction chemotherapy for patients with non-resectable gastric…
- Trial name
- P-HDFL-DI (NCT00166881)
- Testing
- Docetaxel-Irinotecan
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- National Taiwan University Hospital
Triple Negative Breast Cancer
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
This transnational noninterventional study aims to gather real-world evidence on locally recurrent inoperable (hereafter referred to as advanced) or metastatic TNBC (a/m TNBC) biomarker testing, treatment patterns by line of…
- Trial name
- NCT07092254
- Testing
- No drug
- Where
- United States
- Volunteers
- 760 people
- Sponsor
- Daiichi Sankyo
Gastric Cancer
Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers
The primary purpose of the study is to investigate the correlation between the efficacy and toxicity of S-1 on gastric cancers and the expression of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and orotate…
- Trial name
- NCT01650766
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Oncology, Biomarker
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
This non-interventional single-center explorative biomarker study aims at longitudinal comprehensive characterization (molecular genetics, immunological, morphological, image-based and microbial features) of the patient (host)…
- Conditions
- Oncology, Biomarker, NSCLC, Stage III, Durvalumab
- Trial name
- PRECISION (NCT05027165)
- Testing
- Non-interventional
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- LMU Klinikum
Non-small Cell Lung Cancer
Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
The goal of this Single-arm, Phase II clinical trial is to learn whether ablation or stereotactic radiotherapy combined with furmonertinib can treat early-stage non-small cell lung cancer in patients who are inoperable or refuse…
- Trial name
- NCT07517640
- Testing
- furmonertinib, ablation, stereotactic body radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Carcinoma, Pancreatic Ductal
Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma
Patients with inoperable pancreatic cancer have extremely poor prognosis with five year survival below 8% in Norway. Life-prolonging chemotherapy has very limited effect, but is the only therapeutic option for these patients.
- Trial name
- PDAC (NCT04146441)
- Testing
- SonoVue, Chemotherapy
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- St. Olavs Hospital
Cholecystitis, Acute
Endosonography-guided Gallbladder Drainage vs Non-endoscopic Treatment in Inoperable Acute Cholecystitis
In this project the investigators propose to carry out a clinical trial that compares non-endoscopic treatment of cholecystitis with antibiotics versus endoscopic drainage in non-operable acute cholecystitism (AC), especially…
- Trial name
- EUS-DRAIN (NCT05702775)
- Testing
- Endoscopic treatment group (EUS-GBD group
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Fundacion Miguel Servet
Oesophageal Cancer
Role of Radiotherapy Following Oesophageal Stenting in Cancer
To assess the benefits of oesophageal stenting and external beam radiotherapy over oesophageal stenting alone in patients with inoperable oesophageal cancer
- Trial name
- NCT01179074
- Testing
- oesophageal stenting with self expandable metal stent, Oesophageal stent followed by external beam radiotherapy
- Where
- India
- Volunteers
- 84 people
- Sponsor
- All India Institute of Medical Sciences
Non-small Cell Lung Cancer, Breast Cancer
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer.
- Conditions
- Non-small Cell Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT00327288
- Testing
- imexon, docetaxel
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- AmpliMed Corporation
Prostate Cancer
Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate
Cyproterone acetate (CPA) is a steroidal antiandrogen which has affinity with progesterone and with glucocorticoid receptors. Cyproterone acetate is long-term proven effective treatment of inoperable carcinoma of the prostate.
- Trial name
- ANES (NCT00919022)
- Testing
- Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- Czechia
- Volunteers
- 194 people
- Sponsor
- Bayer
Advanced Basal Cell Carcinoma (BCC), Inoperable Disease
Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue
The goal of this clinical trial is to evaluate whether formulated methylene blue can safely and effectively treat advanced or inoperable basal cell carcinoma (BCC), a common type of skin cancer.
- Conditions
- Advanced Basal Cell Carcinoma (BCC), Inoperable Disease, Morpheaform Basal Cell Carcinoma, Noduloulcerative Basal Cell Carcinoma
- Trial name
- NCT07311070
- Testing
- Formulated Topical Methylene Blue (0.5 mg/mL), Wound Healing Gel
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Daryoush Hamidi Alamdari, PhD
Inoperable or Recurrent or Metastatic Esophageal Squamous Carcinoma
A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)
Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Esophageal adenocarcinoma has become more common in Western countries.
- Trial name
- NCT03770988
- Testing
- Treatment with Poziotinib
- Where
- South Korea
- Volunteers
- 49 people
- Sponsor
- Yonsei University